Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Authors

Elizabeth Mittendorf•Melinda Telli•Nadia Harbeck

Journal

The Lancet

Published

September 20, 2020

Sign in to comment

Add a comment...

No comments yet. Start the conversation!

Your contribution could help open science.

Supporters

Support the authors with ResearchCoin

Topics

DOI

10.1016/s0140-6736(20)31953-x

License

Unknown License

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial - Comments